News/Events

Lifordi Immunotherapeutics Presents Phase 1 Clinical Data for LFD-200, a Subcutaneous Glucocorticoid Antibody Drug Conjugate, at EULAR 2026

Lifordi Focuses on Autoimmune Diseases

Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors

Lifordi Immunotherapeutics Presents Nonclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 at ACR 2025 and Initiates Phase 1 Study in Rheumatoid Arthritis

Lifordi Immunotherapeutics to Present New Preclinical Data on Antibody Drug Conjugate LFD-200 Demonstrating Selective and Sustained Delivery of Glucocorticoid Payload to Immune Tissues Without Evidence of Toxicity

Lifordi Immunotherapeutics Presents Preclinical Data on Glucocorticoid Antibody Drug Conjugate LFD-200 to Treat Autoimmune and Inflammatory Diseases at EULAR 2025

Lifordi: Applying ADCs to Autoimmune Conditions

Lifordi Immunotherapeutics Appoints Matthew W. McClure, M.D., as Chief Medical Officer

Lifordi Named Winner of Endpoints 11 as Developer of Antibody Drug Conjugates for Autoimmune and Inflammatory Diseases